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Prompt Reversal of Airway Obstruction Secondary to Angiotensin Converting Enzyme Inhibitor (ACEI) 
 Induced Angioedema by Ecallantide:  A Case Report  
J.R. Cohn, C. McDaniel, N. Richards, C. Au, M. Baram  
Thomas Jefferson University and Hospitals, Philadelphia, PA 19107 
INTRODUCTION 
Case 
 CLINICAL COURSE  AND OUTCOME 
• Fatal airway obstruction from ACEI angioedema has been described 
but effective therapy has not been established.  Intubation is 
sometimes required for progressive airway compromise. Ecallantide is 
a kallikrein pathway blocker and may offer benefit in reversing ACEI 
induced angioedema.  
 
• A 54 year old African-American male with a history of hypertension treated 
with lisinopril daily, remote cocaine abuse associated myocardial infarction, 
seizures and prostate cancer, presented with a 2 day history of facial and throat 
swelling along with dysphagia.  He was treated in the emergency department 
with intravenous methylprednisolone, epinephrine and diphenhydramine.   He 
was admitted, but angioedema progressed overnight, confirmed by 
laryngoscopy.  ICU transfer and intubation was undertaken the next morning 
for airway protection.  Tryptase level was 2 ng/ml.  C3 and C4 and routine 
chemistries were normal.  Ecallantide 30mg was administered subcutaneously 
at 1014 hours.  
• Medications: Lisinopril 10mg daily, tamsulosin. 
• Family History: No history of angioedema.  Parents deceased. 
• Social history.  Denies current alcohol or recreational drug use. 
• Review of Systems: Remarkable for hypertension.  On disability for back and 
knee problems.  
• Physical Exam: Temp 98.8, Respiratory Rate 15, Heart Rate 61, Blood 
Pressure 130/80, and Oxygen Saturation 99% on ventilator.   
•  HEENT- Oral endotracheal tube, limited exam after intubation by 
Otolaryngology for airway obstruction and desaturation while sleeping.   
• Respiratory- Lungs were clear and with good air entry on ventilator.  
• Cardiac- Regular heart rate and regular rhythm with no appreciable gallops, 
murmurs, or rubs.   
• Skin- There was no urticaria, other angioedema or rash.   
CONCLUSION 
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• The mechanism of ACEI angioedema is thought to be from blockade of 
angiotensin converting enzyme, the major enzyme for degradation of 
bradykinin.  
• Bradykinin and substance P have been linked to the pathogenesis of ACEI 
induced angioedema.  Angiotensin converting enzyme (ACE) is a kinase that 
breaks down bradykinin 4. The inhibition of ACE therefore leads to the 
inhibition of bradykinin catabolism.  Bradykinin formation causes 
vasodilatation and increased vascular permeability by interaction with B-2 
receptors.  The inhibition of bradykinin catabolism thus leads to angioedema.  
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in laryngeal angioedema 8.  
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theorized that ecallantide can be used to treat other forms of kallikrein 
dependant angioedema.  
• The length of hospitalization for patients with ACEI induced angioedema has 
ranged from 2 days to 4.8 days 5, 9.  Our patient self-extubated a few hours after 
emergent intubation and was discharged the next day after he remained stable 
overnight and without distress.  
• This case suggests that ecallantide may indeed be effective in the cessation of 
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Fig 1. Glosseal edema (not this patient) 10 
•  Patient improved over the day and self-extubated prior to 1800 hours.  He had 
no dysphagia or difficulty with respiration and was discharged the next 
morning. 
 
•ACEI angioedema is a recognized complication of ACEI treatment that can 
occur months to years after starting therapy.  The incidence is thought to be 0.1-
0.5% (Warner. Ann Pharmacother 2000; 34: 526).  Fatalities from airway 
obstruction are described (Dean. J Forensic Sci 2001; 46: 1239). Angiotensin 
converting enzyme is an important enzyme for degradation of bradykinin. 
Ecallantide selectively and reversibly inhibits plasma kallikrein, preventing 
bradykinin generation. This case suggests that ecallantide may indeed be 
effective in reversing ACEI induced angioedema, even in patients requiring 
intubation for airway protection.  
 
•This presentation was supported in part by Dyax, Inc. 
 
RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tryptase 2ng/ml   Hgb 10.9   pH 7.41   Sodium 145 meq/L   WBC 5.0 K/mm3 
C3 134 mg/dL   PTT 33   PaCO2 33 mmHg   Potassium 3.1 meq/L   Hgb 11.8 gm/dL 
C4 19 mg/dL   PT 14.1   PaO2 110 mmHg   Chloride 105 meq/L   Hct 35.70% 
C2 2.2 mg/dL   INR 1.11   HCO3 21 meq/L   Bicarbonate 30 meq/L   Plt 159 k/mm3 
            Base Excess 0.8 meq   BUN 10 mg/dL   Neutrophils 72.80% 
                  Creatinine 1.1 mg/dL   Lymphocytes 16.10% 
                  Glucose 104 mg/dL   Monocytes 8.70% 
                        Eosinophils 
 
2.20% 
